Versiti Blood Health, Inc.

Versiti Blood Health, Inc., doing business as Versiti Wisconsin Inc., is a non-profit blood center, transfusion medicine organization, and research institution that provides blood collection, processing, testing, storage, and distribution services to the Department of Veterans Affairs and federal research agencies as a prime contractor (94% of recent awards) on delivery orders, indefinite delivery contracts, and federal research grants. The organization competes full-and-open; no set-aside designations appear across the prime footprint.

Versiti's federal customer base is heavily concentrated in the VA healthcare system. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 (VISN 12), based in the Milwaukee region, accounts for 143 awards and $108.4 million in combined potential value—59% of the total prime portfolio and 81% of the top-five customers' combined potential value. The National Heart, Lung, and Blood Institute (NHLBI) ranks second with 63 awards and $32.7 million combined potential value, anchoring the organization's federal research grant portfolio. The Defense Health Agency contributes six awards worth $6.5 million. Notably, the VA dollars derive from recurring delivery orders against three primary single-award indefinite delivery contracts with ceilings ranging from $3.76 million to $13.87 million, while NHLBI funding flows through competitive project grants. Versiti's concrete service delivery spans blood product supply to VA medical centers (firm fixed-price delivery orders ranging from $30,000 to $900,000 per order, renewed annually through September 2026), specialized transfusion medicine testing for the NIH Clinical Center ($11,000 to $14,000 purchase orders), and advanced hematology research including counterflow hemostatic gauze development for the Defense Health Agency (cost-plus-no-fee $6.485 million definitive contract awarded September 2023, with subcontracts to ST Michael's Hospital for in vivo efficacy studies and Comotion Drug Delivery Systems Inc. for analytical method development and GMP manufacturing).

Versiti's research grant portfolio demonstrates breadth across NIH institutes. Recent major grants include $1.18 million from NHLBI for membrane-cytoskeleton interactions in megakaryocytes and platelets (through April 2029), $1.069 million from NHLBI for kindlin-3 signaling in platelets and neutrophils (through December 2032), $679 thousand from the NIH Office of the Director for acquisition of a high-parameter fluorescence-activated cell sorter (through July 2026), $364 thousand from the National Institute of Allergy and Infectious Diseases for memory CD8+ T cell research (through July 2027), and $242 thousand from the National Institute of Diabetes and Digestive and Kidney Diseases for DNA damage responses in hematopoietic stem cells (through August 2027). Additional grants focus on therapeutic development: $1.7 million from the Defense Health Agency for microthrombosis countermeasures in cold injury (through June 2029) and Defense Health Agency support for RNA therapeutics targeting fibrinogen and antifibrinolytic strategies (through August 2027). These grants position Versiti as both a service provider and a research recipient, with the Blood Research Institute serving as the operational center for translational and basic science work.

Activity has grown from 13 awards in 2022 to 30 in 2024, with 23 awards in 2025 and 6 recorded as of July 2026. Twenty-five awards (combined potential value $11.1 million) face ultimate completion inside the next twenty-four months, presenting recompete exposure concentrated in the VA VISN 12 delivery order stream. Across the three single-award VA IDCs, Versiti holds 49 task orders against one vehicle and 35 against another, anchoring recurring revenue. SCI-reportable federal service contract invoicing totaled $3.4 million across fiscal years 2022–2024 (FY2024: $1.3 million across 3.8 FTEs), with government-paid hourly rates running a median of $149.59/hr and a 90th percentile of $796.65/hr, reflecting variation between technician-level blood product processing work and senior researcher labor. Across SCI-reportable prime contracts, subcontractors account for 7 percent of total contractor hours; named subs include ST Michael's Hospital and Comotion Drug Delivery Systems on the Defense Health Agency hemostatic gauze contract. Versiti operates two named subsidiaries: Quantigen, LLC, and Versiti Indiana, Inc., both non-profit entities. The organization's structure reflects integration of operational blood supply delivery, specialized testing services, and a research institute (the Blood Research Institute) that generates both federal grant revenue and scientific output in hematology, transfusion medicine, and translational research.